Technical Innovations & Patient Support in Radiation Oncology 16 (2020) 17–23

Contents lists available at ScienceDirect

Technical Innovations & Patient Support in Radiation Oncology

journal homepage: www.elsevier.com/locate/tipsro

Research article

# Factors affecting radiotherapy utilisation in geriatric oncology patients in NSW, Australia

Penny Mackenzie [a,b,*], Claire Vajdic [c], Geoff Delaney [b], Gabriel Gabriel [b], Meera Agar [d], Tracy Comans [e], Michael Barton [b]

[a] St Andrew's Hospital, Icon Cancer Care, Toowoomba, QLD, Australia
[b] Collaboration for Cancer Outcomes Research and Evaluation, Ingham Institute for Applied Medical Research, South Western Sydney Clinical School, University of New South Wales, Sydney, Australia
[c] University of New South Wales, Sydney, Australia
[d] University of Technology, Sydney, Australia
[e] University of Queensland, Australia

ARTICLE INFO

*Article history:*
Received 9 April 2020
Received in revised form 14 September 2020
Accepted 16 September 2020
Available online 13 October 2020

*Keywords:*
Cancer
Geriatric oncology
Radiotherapy utilisation

ABSTRACT

*Background and Purpose:* Large non-age-specific radiotherapy utilisation rate (RTU) studies have demonstrated that actual RTU is below the optimal recommended utilisation rate for both curative and palliative intent radiotherapy indications. The optimal utilisation rate for the geriatric oncology cohort of patients has not yet been determined. The purpose of this research was to examine the actual RTU for patients treated in New South Wales (NSW), Australia as a function of increasing age, and the relationship between RTU and tumour site, travelling distance and socio-economic status.

*Materials & Methods:* NSW Central Cancer Registry data (2009–2011) were linked to the NSW Radiotherapy Dataset (2009–2012). RTU was calculated for patients aged <80 years and ≥80 years. RTU was defined as the proportion of patients receiving at least a single course of radiotherapy within 12 months of a cancer diagnosis.

*Results:* 110,645 patients were diagnosed with cancer, of whom 27,721 received at least one course of radiotherapy. The overall RTU was 25%. RTU for patients aged <80 years was 28% compared to 14% for patients aged 80+ years ($p < 0.001$). On both univariate and multivariate analysis, increasing age, residential address in disadvantaged socioeconomic areas and increasing distance to the nearest radiotherapy department were associated with a reduction in RTU.

*Conclusion:* Geriatric oncology patients are less likely to receive radiotherapy than their younger counterparts. Some of the reduction in RTU may be justifiable on the basis of limited life expectancy and co-morbidity. Further research is required to determine the co-morbidity adjusted optimal RTU in older patients.



## Introduction

The population of older people for whom cancer treatment needs to be considered is increasing. This is in step with the ageing population and therapeutic advances in oncologic management. In Australia, it has been estimated that approximately 50% of people aged 65 years and above will develop cancer [1], and the overall proportion of people with cancer in this age group is projected to increase from 10-13% (1982–2007) to 17% by 2020 [2]. For patients aged 80–84 years, the number of new cases is projected to increase from 7570 to 9870 for males, and 5030 to 6120 for females, from 2011 to 2020 [2]. Worldwide, it is predicted that the proportion of cancer patients aged 65 years and above will increase from 47.5% (6.7 million patients) in 2012 to 60% (14 million patients) in 2035 [3]. However, there is under-representation of the geriatric (≥80 years) cohort in clinical trials, thus a need for further studies to examine and inform their care [4,5].

Radiotherapy is an important treatment option for older people with cancer. However, limited data are available on current and optimal radiotherapy utilisation (RTU) for older patients. Large, non-age specific RTU studies have demonstrated that actual RTU

* Corresponding author at: St Andrew's Hospital, Department of Radiation Oncology, Icon Cancer Care, 250 North St, Toowoomba, Australia.
*E-mail address:* penny.mackenzie@icon.team (P. Mackenzie).

https://doi.org/10.1016/j.tipsro.2020.09.003
2405-6324/

is below optimal utilisation for both curative and palliative intent radiotherapy schedules [6,7]. The shortfall in overall RTU appears to occur in all major tumour sites, including lung, breast, rectal and prostate cancer. There is evidence that an inappropriate reduction in RTU (non-treatment where evidence suggests benefit) results in decreased local control and overall survival [8–11]. The factors contributing to the reduction in RTU in older cancer patients have not yet been examined.

Improvements in radiotherapy technique are associated with a reduction in side effects [12]. Anecdotally, it is thought that older patients are generally 'fitter' in the current compared to previous eras. Furthermore, the disability-adjusted life year or DALY has reduced in patients aged 80+ years as reported in the Australian Bureau of Statistics disease burden and mortality estimates [13]. This is supported by the literature showing a reduction in functional disabilities in the modern era despite the number of medical co-morbidities increasing with advancing age [14]. Therefore, it is possible that a greater proportion of older patients may benefit from radiotherapy than predicted based on historical experience.

The objectives of this study were to analyse the factors that contribute to a reduction in RTU for people <80 and ≥80 years of age.

## Materials and methods

All patients diagnosed with a notifiable cancer in New South Wales (NSW), Australia, from 2009-2011 were included in the study. NSW Central Cancer Registry data for this period were linked to the NSW Radiotherapy Dataset for 2009–2012. The NSW Central Cancer Registry includes all cancers except for non-melanomatous skin cancers. The radiotherapy dataset includes all patients treated in both the public and private sector. Performance status information was not available.

For the purpose of this research, the geriatric oncology patient group of interest was defined as those ≥80 years of age. In the geriatric oncology literature, the specific cut-off age is described variably. The International Society of Geriatric Oncology (SIOG) [15–18] uses 70 years and above. However, clinical treatment paradigms for radiotherapy often change when patients are ≥80 years of age, when the associated life expectancy is <10 years [19]. Therefore the ≥80 age group was considered of particular interest. Age was categorised into five age groups: <60, 60–69, 70–79, 80–89 and 90+ years.

The actual RTU was calculated by dividing the number of patients who received at least one course of radiotherapy within 12 months of diagnosis by the total number of cases of cancer in a particular population. This methodology has been reported previously [20,21]. The four most common primary cancer sites, breast, prostate, lung and rectal, were chosen to best reflect daily clinical practice, with the International Classification of Diseases, tenth revision (ICD-10) codes of C50, C61, C34 and C20 respectively. RTU rates were compared by age group, primary site, distance to the nearest radiotherapy department and socioeconomic status. Residential postcodes were classified using the census-based Socio-Economic Index for Area (SEIFA) categories based on the Index of Relative Socio-economic Disadvantage (IRSD) [22,23]. Distance to nearest radiotherapy department was examined as both a continuous and categorical variable; a cut-point of 100 km was chosen based on previous research that we have reported [21].

Descriptive statistics were carried out using the Chi-square test or Fisher's exact test for categorical variables. Univariate and multivariate logistic regression analyses were performed to examine the association of RTU with age after taking into account primary site, stage, degree of spread, sex, distance to the nearest radiotherapy department, remoteness and socioeconomic status [22]. Multicollinearity between geographic variables was assessed.

SPSS (SPSS Version 25. Armonk, NY: IBM Corp.), SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and ArcGIS (ESRI 2018. ArcGIS Desktop: Release 10.5 Redlands, CA, USA) were used in statistical analysis. *P* values < 0.05 were considered statistically significant.

## Ethics

Ethics approvals were obtained from all relevant institutional and registry Human Research Ethics Committees.

## Results

### *RTU and age*

Overall, radiotherapy utilisation decreased with increasing patient age (Table 1). RTU for patients aged less than 80 years was 28% compared to 14% for patients aged 80 years and above ($p < 0.001$). In patients aged 70–79 years, the RTU was 25%. The drop off in RTU was most marked from the 80+ year age group.

### *RTU and tumour site*

Radiotherapy utilisation decreased with increasing age from 60 years for all major tumour sites, except for patients with prostate cancer where the peak RTU (35.8%) was observed in the 70–79 year age group and declined thereafter (Fig. 1).

### *RTU and distance to the nearest radiotherapy department*

Fig. 2 shows that for patients residing more than 100 km from the nearest radiotherapy department, patients aged 80 years and above were less likely to receive radiotherapy than younger patients ($p < 0.001$). The correlation was similar for all individual tumour sites.

### *RTU and socio-economic status (IRSD)*

RTU was lowest for patients living in residential areas with the lowest socioeconomic status (Table 2). This effect was consistent for patients aged <80 years and patients aged 80+ years. For example, in patients with breast cancer aged ≥80 years, RTU was 29.6% in the least disadvantaged areas (IRSD-5), compared to 22.8% in the most disadvantaged areas (IRSD-1) ($p < 0.001$). For breast cancer patients younger than 80 years of age, RTU was 68.2% in the least disadvantaged area (IRSD-5) compared to 64.2% in the most disadvantaged areas (IRSD-1) ($p = 0.001$). There was no statistically significant interaction between socioeconomic status and age group on RTU ($p = 0.38$).

**Table 1**
Radiotherapy utilisation within 1 year of diagnosis by patient age.

| Age Group (years) | Total number of patients | Received radiotherapy | RTU rate |
|---|---|---|---|
| <60 | 33 088 | 9726 | 29.4 % |
| 60–69 | 29 706 | 8271 | 27.8 % |
| 70–79 | 26 868 | 6 812 | 25.4 % |
| 80–89 | 17 955 | 2 679 | 14.9 % |
| 90+ | 3 028 | 233 | 7.7 % |
| **Total** | **110 645** | **27 721** | **25.1 %** |
| **<80 years** | **89 662** | **24 809** | **27.7%** |
| **80+** | **20 983** | **2 912** | **13.9%** |




**Fig. 1.** Radiotherapy utilisation rates by tumour site and patient age.




**Fig. 2.** Radiotherapy utilisation(RTU) rates by tumour site, patient age and distance to the nearest radiotherapy department.

*Multivariate analyses*

For all cancers combined, univariate analyses showed age, socioeconomic status and distance were associated with a reduction in RTU (Table 3). All factors significant on univariate analysis were included in the multivariate analysis (Table 4). The multivariate analysis demonstrated that increasing age, residence in areas of socioeconomic disadvantage and increasing distance to the nearest radiotherapy department were significantly associated with a reduction in RTU.

## Discussion

Our Australian population-based research demonstrated a decrease in radiotherapy utilisation with increasing age across all tumour sites except prostate cancer, and with increasing distance to the nearest radiotherapy department. There was a decrease in RTU in older patients from lower compared to higher socioeconomic areas. On univariate and multivariate analysis, increasing age, lower socioeconomic status and greater distance and remoteness were all significantly associated with lower RTU. Our results

**Table 2**
Radiotherapy utilisation rates by tumour site patient age and Index of Relative Socioeconomic Disadvantage (IRSD).

| Tumour site | IRSD* | Number of patients | <80 years | 80 + years | p value |
|---|---|---|---|---|---|
| Lung | IRSD-1 | 2 369 | 42.0% | 23.2% | <0.001 |
| | IRSD-5 | 1 427 | 47.7% | 27.6% | <0.001 |
| Breast | IRSD-1 | 2 322 | 64.2% | 22.8% | <0.001 |
| | IRSD-5 | 3 088 | 68.2% | 29.6% | <0.001 |
| Rectal | IRSD-1 | 784 | 41.5% | 23.9% | <0.001 |
| | IRSD-5 | 576 | 29.6% | 22.7% | 0.17 |
| Prostate | IRSD-1 | 3 676 | 27.0% | 12.8% | <0.001 |
| | IRSD-5 | 4 331 | 18.9% | 17.7% | 0.52 |
| Other | IRSD-1 | 12 887 | 16.4% | 9.6% | <0.001 |
| | IRSD-5 | 12 430 | 16.0% | 10.8% | <0.001 |

* IRSD-1 (most disadvantaged) IRSD-5 (least disadvantaged).

**Table 3**
Univariate analysis of factors affecting RTU.

| Variable | No. of patients | P-value | Odds ratio | 95% C.I. for Odds ratio | |
|---|---|---|---|---|---|
| | | | | Lower | Upper |
| **Age - continuous** | 110,645 | <0.001 | 0.986 | 0.985 | 0.987 |
| **Age - group** | | . | | | |
| < 45 years | 9,145 | <0.001 | 2.265 | 2.132 | 2.406 |
| 45–59 years | 23,943 | <0.001 | 2.714 | 2.587 | 2.847 |
| 60–69 years | 29,706 | <0.001 | 2.396 | 2.287 | 2.510 |
| 70–79 years | 26,868 | <0.001 | 2.109 | 2.011 | 2.213 |
| 80 + years | 20,983 | | 1.000 | | |
| **Sex** | | | | | |
| Males | 62,641 | | 1.000 | | |
| Females | 48,004 | <0.001 | 1.496 | 1.456 | 1.538 |
| **Degree of spread** | | | | | |
| Localised disease | 45,429 | | 1.000 | | |
| Regional disease | 23,550 | <0.001 | 2.323 | 2.244 | 2.404 |
| Distant disease | 17,576 | <0.001 | 1.695 | 1.630 | 1.762 |
| Indeterminate | 24,090 | <0.001 | 0.643 | 0.616 | 0.671 |
| **Country of birth** | | | | | |
| Australian born | 45,590 | | 1.000 | | |
| Overseas born | 21,404 | <0.001 | 1.106 | 1.067 | 1.147 |
| Unknown or missing | 43,651 | <0.001 | 0.754 | 0.731 | 0.777 |
| **Socio-economic status (IRSD)** | | | | | |
| IRSD-1 Most disadvantaged | 22,038 | | 1.000 | | |
| IRSD-2 | 22,334 | 0.306 | 0.978 | 0.936 | 1.021 |
| IRSD-3 | 22,017 | 0.119 | 1.035 | 0.991 | 1.081 |
| IRSD-4 | 22,172 | 0.001 | 1.078 | 1.033 | 1.125 |
| IRSD-5 Least disadvantaged | 21,852 | 0.854 | 0.996 | 0.954 | 1.040 |
| **Residential remoteness** | | | | | |
| Major cities | 78,191 | | 1.000 | | |
| Inner regional | 24,782 | <0.001 | 0.831 | 0.803 | 0.859 |
| Outer regional | 7,061 | <0.001 | 0.767 | 0.723 | 0.814 |
| Remote & very remote | 597 | 0.264 | 0.898 | 0.744 | 1.084 |
| **Residential distance from radiotherapy – continuous** | 110,624 | <0.001 | 0.998 | 0.998 | 0.999 |
| **Residential distance from radiotherapy – group** | | | | | |
| <100 km | 100,031 | | 1.000 | | |
| ≥100 km | 10,593 | <0.001 | 0.765 | 0.728 | 0.803 |

IRSD, Index of Relative Socio-economic Disadvantage.

align with previous age and non-age specific radiotherapy utilisation studies as outlined below [11,31,32,35,36]. Although there has been increasing interest in the medical literature regarding geriatric oncology, reports of age-specific RTU are limited.

In the NSW 45 and Up Study, a reduction in RTU was noted in patients 80+ years of age, although age-specific RTU details were not the subject of this research [24]. The 45 and Up study was a population cohort study which utilised a questionnaire administered in 2006–2009 to 267 153 patients aged from ≥45 years. This dataset was linked to the NSW Cancer Registry and other health databases. 3667 patients were aged 80+ years in this paper (21%) and 18% received radiotherapy (vs 33.8 % in the 60–69 year group). However, there is evidence that the 45 and Up cohort are healthier on average than the general population [25,26].

There is a potential for worsening general medical health and thus suitability and safety for receiving radiotherapy with advancing age. Guidelines have been published by the International Society of Geriatric Oncology (SIOG) on all the major tumour sites including breast, lung, rectal and prostate to guide management for geriatric patients [15–18]. These documents aim to support clinical decision making by increasing knowledge on geriatric oncology. The SIOG guidelines advise treatment recommendations based on a patient's medical co-morbidities and frailty rather than chronological age per se. For example, the breast cancer guidelines state that *'Age alone should not dictate any aspect of management of older individuals with breast cancer. All decisions should consider physiological age, estimated life expectancy, risks, benefits, treatment tolerance, patient preference and potential treatment barriers* [15].'

**Table 4**
Multivariate analysis of factors affecting RTU.

| Variable | No. of patients | P-value | Odds ratio | 95% C.I. for Odds ratio | |
|---|---|---|---|---|---|
| | | | | Lower | Upper |
| Age -continuous | 110,645 | <0.001 | 0.986 | 0.985 | 0.987 |
| Sex | | | | | |
| Males | 62,641 | | 1.000 | | |
| Females | 48,004 | <0.001 | 1.331 | 1.294 | 1.369 |
| Degree of Spread | | | | | |
| Local disease | 45,429 | | 1.000 | | |
| Regional disease | 23,550 | <0.001 | 2.276 | 2.198 | 2.357 |
| Metastatic disease | 17,576 | <0.001 | 1.755 | 1.686 | 1.827 |
| Indeterminate | 24,090 | <0.001 | 0.695 | 0.665 | 0.725 |
| Country of birth | | | | | |
| Australian born | 45,590 | | 1.000 | | |
| Overseas born | 21,404 | 0.031 | 1.043 | 1.004 | 1.083 |
| Unknown or missing | 43,651 | <0.001 | 0.761 | 0.737 | 0.786 |
| Socio-economic status | | | | | |
| IRSD-1 (most disadvantaged) | 22,038 | | 1.000 | | |
| IRSD-2 | 22,334 | 0.895 | 0.997 | 0.953 | 1.043 |
| IRSD-3 | 22,017 | 0.811 | 1.006 | 0.961 | 1.052 |
| IRSD-4 | 22,172 | 0.816 | 1.005 | 0.960 | 1.053 |
| IRSD-5 (least disadvantaged) | 21,852 | <0.001 | 0.912 | 0.870 | 0.956 |
| Residential remoteness | | | | | |
| Major cities | 78,191 | | 1.000 | | |
| Inner regional | 24,782 | 0.011 | 0.947 | 0.908 | 0.988 |
| Outer regional | 7,061 | 0.379 | 1.039 | 0.954 | 1.132 |
| Remote and very remote | 597 | <0.001 | 1.736 | 1.361 | 2.215 |
| Residential distance from radiotherapy - continuous | 110,624 | <0.001 | 0.998 | 0.998 | 0.999 |

However, there is little agreement about what performance assessment and scores should be used and there is likely to be high variability in fitness assessment.

Various performance scores may be used to assist in patient selection for treatment. The ECOG performance score, introduced in the 1960′s, is well-established; assessing patient's function and independence and thus suitability of treatment [27]. Unfortunately, there is incomplete recording of patients' ECOG performance status in our dataset. Other methods may be used to assess functional status [28–30]. The multiple scoring systems highlight the importance of performance status and co-morbidities in treatment decision making, but also the difficulty in attaining consensus criteria to help guide management and then train oncologists in their application, and no attempts to routinely collect these data.

In our research, a reduction in RTU was noted across different tumour sites. The following tumour-site specific articles in the literature also report a reduction in RTU across different tumour sites. Vinod et al., demonstrated a reduction in lung radiotherapy utilisation with increasing age, even in patients of good performance status (ECOG 0-2) [31]. McAleese et al. reported that the elderly, defined as age $\geq$70 years, were less likely to receive guideline-recommended curative intent treatment for non-small cell lung cancer compared to younger patients (40% vs. 60%) [32]. More recently, with advances in treatment techniques and greater access to specialised including stereotactic radiotherapy treatments, there is evidence of increased radiotherapy utilisation in elderly lung cancer patients, with utilisation increasing from 26% to 42% from 1999-01 to 2005–07 [33] as more elderly patients are offered curative radiotherapy as an alternative to surgery. Videtic et al. reported on their single institution experience of stereotactic radiotherapy in patients with lung cancer 90 years of age or older and concluded that radiotherapy is safe and effective in this age group [34].

The current literature also demonstrates a decrease in RTU for breast cancer with increasing age. Struikmans et al. reported a reduction in radiotherapy utilisation following breast-conserving surgery with increasing patient age, particularly in patients aged are $\geq$75 years, finding an odds ratio of 0.13 for this patient group versus patients less than or equal to 50 years of age [11]. Showalter et al. on examining the SEER database, demonstrated a reduction for adjuvant radiotherapy in stage I breast cancer patients 80 years of age and above following breast-conserving surgery, with a RTU of 6.4% [35].

Radiotherapy utilisation is reduced with increasing age in rectal cancer patients. Jobson et al. demonstrated, in a population-based study in the Netherlands 1997–2008, that pre-operative radiotherapy decreased to 17%-26% for patients aged 85–89 years compared with 47–69% in patients aged 60–64-years [36].

There is less data available in the literature on radiotherapy benefits for older patients with prostate cancer. Of note, the SIOG Task Force stated that if patients are elderly but fit, standard treatment is recommended [16]. Prostate RTU increased up until age 80 contrary to the findings for other cancers, perhaps because surgery is offered or accepted less frequently in prostate cancer patients with advancing age and low fitness. For the other major tumour sites, the radiotherapy offered is more frequently adjuvant therapy, and appears to be considered less important with increasing age. For some tumour sites such as breast cancer, this may be entirely appropriate when other competing adjuvant therapies may adequately reduce recurrence risk (such as early, ER-positive breast cancer being managed with adjuvant endocrine therapy in preference to radiotherapy) [37]. However, for other tumour sites, such as rectal cancer, this reduction in radiotherapy utilisation may or may not be appropriate depending on the predicted patient prognosis and their locoregional recurrence risk.

With regards to place of residence and distance to the nearest radiotherapy department, our results are similar to an earlier NSW study using a 2004–2006 dataset [21]. With an increase in the number of regional centres in recent years, it is expected that RTU may increase [7].

The duration of treatment, and the provision of shorter or 'hypo-fractionated' courses of radiotherapy may also increase the RTU in the older cohort of patients, with less treatment attendances required. Of note, certain hypo-fractionated radiotherapy schedules for specific cancer sites are considered standard of care for patients of all ages, for example, the breast cancer hypo-fractionated regimens [38,39].

Socioeconomic status is known to affect delivery of care and cancer outcomes and may also correlate with the presence of co-morbidities. Galvin et al. in their systematic review, demonstrated that low socioeconomic status and advancing age were associated with poorer cancer specific and overall survival [40]. There are limited data on the relationship between socioeconomic status and RTU in older patients. Hui et al. reported on the socioeconomic status and patterns of care in NSW patients with lung cancer and found no difference in RTU rates based on IRSD categories [41]. However, less than 12% of patients were aged 70 years and above in this older study (with the patient population from January 1996-December 1996).

A concern by treating and referring clinicians may be the tolerance of radiotherapy toxicity in the elderly cohort of patients. There is research showing older patients can be safely treated with radiotherapy. A French multicentre retrospective study showed that radiotherapy was safe in patients 90 years of age or older [42]. This age group was reported to represent approximately 1% of patients treated in their centres. Kocik et al., reported that 41% of patients aged 90 years and above evaluated at their Austrian Cancer Centre (2005–2016) received definitive radiotherapy in their retrospective study [43], and 90% of these patients completed their course of treatment. The modern radiotherapy treatment techniques are also associated with a reduction in side effects, with an increase in the precision and accuracy of treatment [44].

Whilst appropriate treatment decisions are essential and expected, it is also important to note that if radiotherapy is withheld, the prognosis may be worse. The inferior clinical outcomes associated with the underutilisation of radiotherapy have been previously reported. In a younger cohort, of patients, there is a reduction in local control and survival if RT is not administered [20,45]. Hanna et al. reported that RT is associated with a 5-year improvement in local control in 10.4% and 5-year overall survival benefit in 2.4% in all patients [45]. The appropriate utilisation of radiotherapy is also potentially more important in geriatric patients if other treatment options, such as surgery and systemic therapies, are limited. Research exploring this topic is unfortunately limited.

The strengths of this research were the population-based study design, and the large number of cases. To our understanding, this is the first time that geriatric oncology RTU across multiple cancer sites using a large cancer registry has been reported in the literature. The limitations were the lack of ECOG performance status data and thus ability to determine the appropriate RTU in this cohort of patients. Other relevant data that were not present in this database include receipt of surgery, chemotherapy or targeted therapy, patient preference and caregiver availability.

## Conclusion

Radiotherapy utilisation rates decreased with increasing age except for prostate cancer. This reduction in RTU rates occurs across the major tumour sites, in patients of lower socioeconomic status and with increasing distance from radiotherapy departments. Further research is required to estimate the appropriate proportion of geriatric patients who should receive radiotherapy and to examine reasons for any gap. The development of a co-morbidity/frailty adjusted score for optimal radiotherapy utilisation rate would assist in clinical decision making, especially in the era of personalised medicine.

## Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Acknowledgement

This study was funded by Cancer Institute NSW, Australia.

## References

[1] Cancer in Australia in 2017, AIHW - Australian Institute of Health and Welfare (AIHW) 2017. All cancers combined. Canberra: AIHW. [Accessed July 2017].
[2] https://www.aihw.gov.au/reports/cancer/cancer-incidence-projections-australia-2011-to-20/data.
[3] Pilleron S, Sarfati D, Janssen-Heijnen M, et al. Global cancer incidence in older adults, 2012 and 2035: A population-based study. Int J Cancer 2019;144:49–58.
[4] Hutchins L, Crowley UJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;1341(27):2061–7.
[5] Scher K, Hurria A. Under-representation of Older adults in cancer registration trials: known problems, little progress. J Clin Oncol 2012;30(17):2036–8.
[6] Barton M, Jacob S, Delaney G, et al. Estimating the demand for radiotherapy from the evidence: A review of changes from 2003–2012. Radiother Oncol 2014;112:140–4.
[7] Barton M, Delaney G. A decade of investment in radiotherapy in New South Wales: Why does the gap between optimal and actual persist? JMIRO 2011;22:433–41.
[8] Shafiq J, Hanna T, Vinod S, Delaney G, Barton M. A Population-based model of local control and survival benefit of radiotherapy for lung cancer. Clin Oncol 2016;28:627–38.
[9] Merie R, Gabriel G, Shafiq J, Vinod S, Barton M, Delaney G. Radiotherapy underutilisation and its impact on local control and survival in New South Wales, Australia. Radiotherapy Oncol 2019;141:41–7.
[10] Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15 year survival: an overview of the randomised trials. Lancet 2005;366:2087–106.
[11] Struikmans H, Aarts M, Jobsen J, et al. An increased utilisation rate and better compliance to guidelines for primary breast radiotherapy for breast cancer from 1997–2008: A population-based study from the Netherlands. Radiother Oncol 2011;100:320–5.
[12] Baumann M, Krause M, Overgaard J, et al. Radiation oncology in the era of precision medicine. Nat Rev 2016;16:234–49.
[13] Australian Bureau of Statistics, Australian Burden of Disease Study 2015: Impact and Causes of Illness and Death in Australia. Published June 2019. https://www.aihw.gov.au/reports-data/health-conditions-disability-deaths/burden-of-disease/overview.
[14] Christensen K, Doblhammer RG, Rau R, et al. Ageing populations: the challenges ahead. Lancet 2009;374:1196–208.
[15] Biganzoli L, Wildiers H, Oakman C, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast cancer Specialists (EUSOMA). Lancet Oncol 2012;13:e148–60.
[16] Droz J-P, Albrand G, Gillessen S, et al. Management of prostate cancer in elderly patients: recommendations of a task force of the international society of geriatric oncology. Eur Urol 2017;72:521–31.
[17] Pallis A, Gridelli C, Wedding U, et al. Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Ann Oncol 2014;25(7):1270–83.
[18] Montroni I, Ugolini G, Saur N, et al. Personalized management of elderly patients with rectal cancer: Expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer. Eur J Surg Oncol 2018;44:1685–702.
[19] Australian Institute of Health and Welfare (AIHW), Deaths in Australia. Life expectancy (expected age at death in years) at different ages by sex, 1881-1890 to 2016-2018, Table S6.1 [Accessed September 2020].
[20] Batumalai V, Shafiq J, Gabriel G, Hanna T, Delaney G, Barton M. Impact of radiotherapy underutilisation measured by survival shortfall, years of potential life lost and disability-adjusted life years lost in New South Wales, Australia. Radiotherapy Oncol. 2018;129:191–5.
[21] Gabriel G, Barton M, Delaney G. The effect of travel distance on radiotherapy utilization in NSW and ACT. Radiother Oncol 2015;117:386–9.
[22] Australian Bureau of Statistics. 2016 Census of Population and Housing. Socioeconomic Indexes for Areas. Australian Bureau of Statistics, Australia, 2016. ABS Catalogue No. 2033.0.55.001
[23] https://www1.health.gov.au/internet/publications/publishing.nsf/Content/ARIA-Review-Report-2011~ARIA-Review-Report-2011-2~ARIA-Review-Report-2011-2-2-3 [accessed 25 February 2020].
[24] Yap M, O'Connell D, Goldsbury D, Weber M, Barton M. Factors associated with radiotherapy utilisation in New South Wales, Australia: Results from the 45 and Up Study. Clin Oncol 2020;32(5):282–91.
[25] Creighton N, Purdie S, Soeberg M, et al. Self-selection in a population-based cohort study: impact on health service use and survival for bowel and lung cancer assessed using data linkage. BMC Med Res Method 2018;18:84.

[26] Mealing N, Banks E, Jorm L, et al. Investigation of relative risk estimates from studies of the same population with contrasting response rates and designs. BMC Med Res Method 2010;10:26.
[27] Oken M, Creech R, Tormey et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5: 649–55.
[28] Stanley J, Sarfati D. The new measuring multimorbidity index predicted mortality better than Charlson and Elixhauser indices among the general population. J Clin Epidem. 2017;92:99–110.
[29] Charlson M, Pompei P, Ales K. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40(5):373–83.
[30] Elixhauser A, Steiner C, Harris D. Comorbidity measures for use with administrative data. Med Care 1998;36:8–27.
[31] Vinod S, Barton M. Actual versus optimal utilisation of radiotherapy in lung cancer: Where is the Shortfall. Asia Pacific J Clin Onc 2007;3:30–6.
[32] McAleese J, Baluch S, Drinkwater K, et al. The elderly are less likely to receive recommended radical radiotherapy for non-small cell lung cancer. Clin Oncol 2017;29:593–600.
[33] Palma D, Bisser O, Lagerwaard J, et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small cell lung cancer: A population-based time-trend analysis. JCO. 2010;28(35):5153–9.
[34] Videtic G, Woody N, Reddy C, Stephans K. Never too old: A single institution experience of stereotactic body radiation therapy for patients 90 years and older with early stage lung cancer. Practical Radiat Oncol 2017;7:e543–9.
[35] Showalter S, Grover S, Sharma et al. Factors influencing surgical and adjuvant therapy in stage I breast cancer: A SEER 18 database analysis. Ann Surg Oncol. 2013;20:1287–94.
[36] Jobsen J, Aarts M, Siesling S, et al. The Use of primary radiotherapy for rectal cancer in the Netherlands between 1997 and 2008: A population-based study. Clin Oncol 2012;24:e1–8.
[37] Hughes K, Schnaper L, Bellon J, et al. Lumpectomy plus tamoxifen with or without irradiation in women aged 70 years or older with early breast cancer: long term follow -up of CALGB 9343. J Clin Onc 2013;31(19):2382–7.
[38] Haviland J, Owen J, Dewar J, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10- year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086–94.
[39] Whelan T, Pignol J-P, Levine et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–20.
[40] Galvin A, Delva F, Helmer C, et al. Sociodemographic, socioeconomic, and clinical determinants of survival in patients with cancer: A systematic review of the literature focused on the elderly. J Geriatric Oncol 2018;9:6–14.
[41] Hui A, Vinod S, Jalaludin B, Yuile P, Delaney G, Barton M. Socio-economic status and patterns of care in lung cancer. Aust N Z J Public Health 2005;29(4):372–7.
[42] Chargari C, Moriceau G, Magne N. Feasibility of radiation therapy in patients 90 years of age and older: A French multicentre analysis. Eur J Cancer 2014;50:1490–7.
[43] Kocik L, Geinitz H, Track C, et al. Feasibility of radiotherapy in nonagenarian patients: a retrospective study. Strahlenther Onkol 2019;195:62–8.
[44] Bhide S, Nutting C. Recent advances in radiotherapy. BMC Med 2010;8:25–9.
[45] Hanna T, Shafiq J, Delaney G, Vinod S, Thompson S, Barton M. The population benefit of evidence-based radiotherapy: 5- year local control and overall survival benefits. Radiother Oncol 2018;126:191–7.